DC cell-based hepatitis B virus T epitope peptide

Abstract

The invention relates to the field of protein engineering, gene engineering and biomedicine, and particularly relates to a DC cell-based hepatitis B virus T epitope peptide. According to the technical scheme, the DC cell-based hepatitis B virus T epitope peptide is characterized by consisting of 9 amino acid residues with an amino acid sequence of QLFHLCLII. According to the DC cell-based hepatitis B virus T epitope peptide, basic amino acid is used as a framework, a solid-phase synthesis technology is adopted, a same preset amino acid sequence is simultaneously synthesized on the framework; with the hepatitis B virus as a design target, and the DC cell-based hepatitis B virus specific epitope peptide is produced by adopting a synthesis technology; the epitope peptide is loaded in-vitro on the DC cell, the mature DC cell is infused into bodies of specific people, and generation of the specificity is capable of eliminating the hurt caused by hepatitis B virus infection and particularly cleaning viruses in the body and improving the clinical syndromes against acute hepatitis B.

Description

[0001] This application is a divisional application with an application date of March 25, 2011, an application number of 201110073862.3, and an invention title of "A Hepatitis B Virus T Epitope Peptide Based on DC Cells". technical field [0002] The invention relates to the fields of protein engineering, genetic engineering and biomedicine, in particular to a DC cell-based hepatitis B virus T epitope peptide. Background technique [0003] Worldwide, more than 400 million people are infected with the hepatitis B virus, and 1 million people die each year from complications of the infection, including cirrhosis, hepatocellular carcinoma, or other complications. Most of the prior art uses traditional Chinese medicine or western medicine to treat hepatitis B. Although it has a certain effect, it cannot cure hepatitis B or other complications, especially it cannot effectively block liver fibrosis and cirrhosis caused by hepatitis B virus infection, and block the passage of hepatit...

AI Technical Summary

Problems solved by technology

Most of the prior art uses traditional Chinese medicine or western medicine to treat hepatitis B. Although it has a certain effect, it cannot cure hepatitis B or other complications, especially it cannot effectively block liver fibrosis and cirrhosis caused by hepatitis B virus infection, and block the passage of hepatitis B virus. The placenta transmits to the fetus and blocks the transmission of hepatitis B virus to breastfed newborns through milk

Images